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IMPORTANCE The fact that individuals with schizophrenia have high cardiovascular morbidity
and mortality is well established. However, risk status and moderators or mediators in the
earliest stages of illness are less clear.
OBJECTIVE To assess cardiometabolic risk in first-episode schizophrenia spectrum disorders
(FES) and its relationship to illness duration, antipsychotic treatment duration and type, sex,
and race/ethnicity.
DESIGN, SETTING, AND PARTICIPANTS Baseline results of the Recovery After an Initial
Schizophrenia Episode (RAISE) study, collected between July 22, 2010, and July 5, 2012, from
34 community mental health facilities without major research, teaching, or clinical FES
programs. Patients were aged 15 to 40 years, had research-confirmed diagnoses of FES, and
had less than 6 months of lifetime antipsychotic treatment.
EXPOSURE Prebaseline antipsychotic treatment was based on the community clinician’s
and/or patient’s decision.
MAIN OUTCOMES AND MEASURES Body composition and fasting lipid, glucose, and insulin
parameters.
RESULTS In 394 of 404 patients with cardiometabolic data (mean [SD] age, 23.6 [5.0] years;
mean [SD] lifetime antipsychotic treatment, 47.3 [46.1] days), 48.3% were obese or
overweight, 50.8% smoked, 56.5% had dyslipidemia, 39.9% had prehypertension, 10.0%
had hypertension, and 13.2% had metabolic syndrome. Prediabetes (glucose based, 4.0%;
hemoglobin A1c based, 15.4%) and diabetes (glucose based, 3.0%; hemoglobin A1c based,
2.9%) were less frequent. Total psychiatric illness duration correlated significantly with higher
body mass index, fat mass, fat percentage, and waist circumference (all P < .01) but not
elevated metabolic parameters (except triglycerides to HDL-C ratio [P = .04]). Conversely,
antipsychotic treatment duration correlated significantly with higher non–HDL-C,
triglycerides, and triglycerides to HDL-C ratio and lower HDL-C and systolic blood pressure (all
P  .01). Olanzapine was significantly associated with higher triglycerides, insulin, and insulin
resistance, whereas quetiapine fumarate was associated with significantly higher triglycerides
to HDL-C ratio (all P  .02).
CONCLUSIONS AND RELEVANCE In patients with FES, cardiometabolic risk factors and
abnormalities are present early in the illness and likely related to the underlying illness,
unhealthy lifestyle, and antipsychotic medications, which interact with each other.
Prevention of and early interventions for psychiatric illness and treatment with lower-risk
agents, routine antipsychotic adverse effect monitoring, and smoking cessation interventions
are needed from the earliest illness phases.
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S chizophrenia spectrum disorders are associated with2- to 3-fold excess mortality1-3 and a 10- to 30-year gapin life expectancy4-7 that has been widening2,8-11 com-
pared with the general population. Whereas secondary and ter-
tiary prevention has improved in the general population,8,12,13
people with schizophrenia receive inadequate care for physi-
cal illnesses12,14-17 despite available guidelines.18 The vast ma-
jority of this group’s premature mortality is related to cardio-
vascular illness and obesity-related cancers.4,7,11,13,19 Reasons
for the excess cardiovascular risk are complex, involving
schizophrenia-related factors, poverty, unhealthy lifestyle, sub-
optimal medical monitoring and care, and adverse effects of
treatment.13,20,21
Because cardiovascular risk factors may develop
quickly22-24 and overweight or obesity can lead to diabetes
mellitus and coronary heart disease risk,25 even if weight is lost
later in life,26 patients with first-episode schizophrenia spec-
trum disorders (FES) require attention to both psychiatric and
medical health. Although antipsychotics are the cornerstone
of FES treatment27 and reduce psychiatric symptoms and over-
all mortality,28,29 they can cause cardiometabolic adverse
effects20,21 that should be prevented.30 Unfortunately, little is
known about the trajectory of cardiometabolic risk as pa-
tients progress through their illness. Further, FES data are
scarce and largely limited to samples assessed in controlled
trials and/or academic settings.
To better characterize the cardiometabolic health of pa-
tients with FES and its relationship to sex, race/ethnicity, ill-
ness duration, and antipsychotic treatment, we report base-
line data from patients with FES enrolled in a prospective
treatment study at 34 real-world community mental health
clinics across the United States.
Methods
As part of the National Institute of Mental Health–funded Re-
covery After an Initial Schizophrenia Episode–Early Treat-
ment Program (RAISE-ETP) study, we examined the cardio-
vascular health of individuals with FES. Baseline data were
collected from July 22, 2010, through July 5, 2012. The study
was approved by the North Shore–LIJ Health System Institu-
tional Review Board and/or local site institutional review
boards. Adults provided written informed consent; patients
younger than 18 years provided written assent, with legal
guardians providing written informed consent.
Study Design
The RAISE-ETP study is a cluster-randomized comparison of
NAVIGATE, an integrated program of medication treatment
guided by a decision support system, individual psycho-
therapy, family psychoeducation, and supported employ-
ment or education vs community care determined by the cli-
nician’s or patient’s choice. Sites included 34 community
mental health centers without major research, teaching, or
clinical first-episode programs, located in diverse communi-
ties ranging from semirural to large urban (eAppendix 1 in the
Supplement).
Patients and Treatment
The following were inclusion criteria for the patients: (1) being
aged 15 to 40 years (1 patient was aged 51 years; a protocol ex-
ception was filed); (2) being diagnosed as having schizophre-
nia, schizophreniform disorder, schizoaffective disorder, psy-
chotic disorder not otherwise specified, or brief psychotic
disorder; (3) having less than 6 months of cumulative antipsy-
chotic use (defining first episode); and (4) being proficient in
English. The following were exclusion criteria: (1) being diag-
nosed as having bipolar disorder, major depressive disorder
with psychosis, substance-induced psychotic disorder, or psy-
chotic disorder due to a general medical condition; (2) having
current neurological disorders affecting diagnosis or progno-
sis; and (3) having clinically significant head trauma or an-
other serious medical condition. The inclusion and exclusion
of patients are shown in Figure 1. Any treatment received prior
to study participation or assessment was based on the com-
munity clinician’s and/or patient’s choice.
Assessment
Assessments pertinent herein documented prescribed medi-
cation, demographic, psychosocial, illness duration, medical
and substance use information (based on site personnel in-
terview of the patient or informants with or without medical
record review). Race and ethnicity were coded based on pa-
tient or informant information and assessed because these vari-
ables have been associated with cardiovascular risk factors and
illness in the general population. Diagnoses were determined
using the Structured Clinical Interview for DSM-IV Axis I Dis-
orders, Patient Edition31 by centralized, expert interviewers
conducting live, 2-way video patient interviews. Tobacco smok-
ing status was obtained with the Fagerström questionnaire.32
Patients underwent research assessments of height (Seca
217 stadiometer), weight plus fat mass and percentage (Tanita
TBF-310GS scale), waist circumference, and systolic and dia-
stolic blood pressure as well as fasting phlebotomy for elec-
trolytes, liver and renal function, and levels of hemoglobin A1c
(HbA1c), insulin, and lipids. Fasting glucose level was as-
sessed clinically and collected from the patients’ records.
For definitions and thresholds33-41 for body composi-
tion and cardiometabolic outcomes, see eAppendix 2 in the
Supplement.
Statistical Analysis
Except for HDL-C and HbA1c, all metabolic parameter analy-
ses were restricted to the 286 patients (94.1%) with fasting
blood test results. Extreme outlying data were capped at 4 SDs
above the mean for fasting triglycerides, glucose, and insulin
in 1 individual each. One patient with type 1 insulin-
dependent diabetes was excluded from the analysis of glu-
cose, insulin, and homeostasis model assessment–estimated
insulin resistance. Beyond descriptive analyses of the entire
sample, categorical and continuous cardiovascular variables
were compared by sex, race, ethnicity, and antipsychotic-
naive vs antipsychotic-exposed status using χ2 test and t test
or Fisher exact test as appropriate. Racial subgroups were com-
pared using post hoc pairwise t test. No further adjustments
for multiple comparisons were made. Because of nonnormal
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distribution of duration of illness and antipsychotic treat-
ment, Spearman ρ was used to assess correlations between
these variables and continuous cardiometabolic variables (pro-
viding more power than categorical outcomes). Exploratory
linear regression analyses of continuous cardiometabolic vari-
ables were performed to evaluate the contribution of specific
second-generation antipsychotics (excluding asenapine, cloza-
pine, and lurasidone hydrochloride [each n < 10]), first-
generation antipsychotics (grouped together), antipsychotic
polypharmacy, and no baseline antipsychotic treatment (en-
tering treatment groups as binary variables). For analyses of
body composition and blood pressure, linear regression mod-
els were adjusted for sex, age, race, and ethnicity. Because pa-
tients taking quetiapine fumarate had significantly higher fat
percentage, all metabolic outcome models were additionally
adjusted for fat percentage. Analyses were conducted with JMP





The RAISE-ETP sample consists of 404 patients; 394 (97.5%)
had 1 or more baseline assessments of body mass index
(BMI; calculated as weight in kilograms divided by height in
meters squared), blood pressure, or metabolic assessment,
composing the study sample (Figure 1). The mean (SD) age
of patients was 23.6 (5.0) years; 73.1% of patients were male;
81.5% were non-Hispanic; and 54.6% were white (Table 1).
Diagnoses included schizophrenia (53.8%), schizoaffective
disorder (20.1%), schizophreniform disorder (16.0%), and
psychotic disorder not otherwise specified or brief psy-
chotic disorder (10.2%).
At baseline, 56.9% were referred from outpatient settings
and 78.4% had at least 1 psychiatric hospitalization; 86.3% had
received antipsychotics, of which 92.4% were second-
generation antipsychotics (Table 1). The mean (SD) total life-
time antipsychotic treatment was 47.3 (46.1) days (95% CI, 42.7-
51.9). Other psychotropic medications consisted mainly of
antidepressants (32.0%), anticholinergics (17.3%), mood sta-
bilizers (12.2%), and benzodiazepines (11.2%).
Males were significantly younger than females at first psy-
chotic symptom onset (P = .04) and baseline (P < .001) (Table 1).
More females than males had schizoaffective disorder (P < .001)
and received antidepressants (P = .001) and benzodiazepines
(P = .009). Racial groups did not differ significantly regarding
sex (P = .09), age (P = .59), baseline antipsychotic treatment
group (P = .32), or antipsychotic treatment duration (P = .97).
Among all patients, 50.8% smoked cigarettes; signifi-
cantly more males than females smoked (55.9% vs 36.8%, re-
spectively; P < .001) (Table 2). No patient received nicotine re-
placement or medication treatment for smoking (Figure 2).
Body Composition
The mean (SD) BMI was 26.6 (6.7); 48.3% of patients were obese
(22.1%) or overweight (26.2%) (Table 2). Females compared with
males had significantly higher fat mass (mean [SD], 25.3 [16.3]
vs 16.6 [13.4] kg, respectively; P < .001) and fat percentage
(mean [SD], 32.5% [10.8%] vs 19.0% [9.5%], respectively;
P < .001). Black patients had significantly higher fat mass than
white patients (mean [SD], 21.6 [17.6] vs 18.0 [12.9] kg, respec-
tively; P = .03) (Table 3).
Arterial Hypertension
Among the patients, 39.9% had prehypertension and 10.0% had
hypertension but only 3.6% received antihypertensive drugs
Figure 1. Flow Diagram of Study Participants
10 Excluded (no cardiometabolic data)
11 Not enrolled
4 Lost contact
3 Moved from area
2 Declined participation
1 Incarcerated
1 Did not meet criteria
88 Not eligible
41 Did not meet criteria
20 Lost contact
3 Other




415 Eligible for enrollmente
503 Consentedc
371 Did not consent
109 Lost contact with client
105 Did not want research
49 Did not want treatment
43 Unable to return to clinic
36 Other
22 Unable to consent
7 Did not want to leave clinician
874 Meeting screening eligibility criteriab
433 Not eligible
163 Used antipsychotic >6 mo
112 Psychiatric diagnosis
83 Not first episode
51 Not meeting age criteria
24 Neurological issues or head trauma
Completed eligibility interviewd
1307 Screeneda
a Potential research participants contacted by research staff.
b Potential participants meeting brief (preconsent) checklist.
c Potential participants who signed informed consent and agreed to participate
in the study if eligibility criteria were met.
d After signing informed consent, patients submitted to diagnostic eligibility
interview, during which major inclusion and exclusion criteria were assessed.
e For patients meeting eligibility on the diagnostic interview, enrollment into
treatment occurred at the end of the baseline 2 visit, during which the final
eligibility criteria were assessed.
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(Table 2 and Figure 2). Males had significantly higher systolic
(P < .001) and diastolic (P = .01) blood pressure and more fre-
quent prehypertension (P < .001) than females, who received
more antihypertensives (P = .047).
Lipid Metabolism
Altogether, 56.5% had at least 1 abnormality in low-density
lipoprotein cholesterol, non–high-density lipoprotein
cholesterol (HDL-C), HDL-C, or triglycerides level but
only 0.5% received lipid-lowering medications (Table 2
and Figure 2). Males had lower HDL-C (P < .001) and
higher triglycerides (P = .03) (Table 2). White patients
compared with black patients had higher triglycerides
(P < .001), more hypertriglyceridemia (P = .002) and dyslip-
idemia (P < .001), and lower HDL-C (P < .001) (Table 3). His-
panic patients had more dyslipidemia than non-Hispanic
patients, driven by more elevated non–HDL-C (both P = .03)
(Table 3).







(n = 106) P Value
Age, mean (SD), y 23.6 (5.0) 23.1 (4.4) 25.0 (6.3) <.001
Age at first psychiatric illness,
mean (SD), y
16.9 (6.5) 16.7 (6.2) 17.5 (7.0) .28
Duration since onset of any first
psychiatric illness, mean (SD), y
6.7 (6.7) 6.4 (6.3) 7.6 (7.9) .13
Duration of untreated psychosis,
median (IQR), wk
84.6 (25.9-270.9) 76.7 (24.9-280.9) 105.1 (31.6-260.0) .31
Age at first psychotic symptoms,
mean (SD), y
19.0 (6.2) 18.6 (5.5) 20.1 (7.9) .04
Non-Hispanic ethnicity, No. (%) 321 (81.5) 229 (79.5) 92 (86.8) .10
Race, No. (%)
White 215 (54.6) 165 (57.3) 50 (47.2)
.09
Black 144 (36.6) 96 (33.3) 48 (45.3)
Native American 22 (5.6) 19 (6.6) 3 (2.8)
Asian 12 (3.1) 7 (2.4) 5 (4.7)
Hawaiian 1 (0.3) 1 (0.4) 0
Educational level, No. (%)
Patient (n = 393)
Postgraduate degree 1 (0.3) 0 1 (1.0)
.30
Some postgraduate education 9 (2.3) 7 (2.4) 2 (1.9)
4 y of college 14 (3.6) 7 (2.4) 7 (6.7)
Some secondary education 99 (25.2) 69 (24.0) 30 (28.6)
High school diploma 128 (32.6) 97 (33.7) 31 (29.5)
High school 125 (31.8) 95 (33.0) 30 (28.6)
Eighth grade 12 (3.1) 9 (3.1) 3 (2.9)
None 5 (1.3) 4 (1.4) 1 (1.0)
Maternal (n = 327)
Postgraduate degree 17 (5.2) 16 (6.7) 1 (1.1)
.04
Some postgraduate education 9 (2.8) 7 (2.9) 2 (2.3)
4 y of college 62 (19.0) 44 (18.5) 18 (20.2)
Some secondary education 75 (22.9) 61 (25.6) 14 (15.7)
High school diploma 106 (32.4) 76 (31.9) 30 (33.7)
High school 37 (11.3) 20 (8.4) 17 (19.1)
Eighth grade 14 (4.3) 10 (4.2) 4 (4.5)
None 7 (2.1) 4 (1.7) 3 (3.4)
Primary SCID diagnosis, No. (%)
Schizophrenia 212 (53.8) 161 (55.9) 51 (48.1)
.004
Schizoaffective disorder 79 (20.1) 45 (15.6) 34 (32.1)
Schizophreniform disorder 63 (16.0) 50 (17.4) 13 (12.3)
Psychotic disorder
not otherwise specified
40 (10.2) 32 (11.1) 8 (7.6)
Outpatient treatment setting
at baseline, No. (%)
224 (56.9) 155 (53.8) 69 (65.1) .20
Duration of antipsychotic
treatment, mean (SD), d
47.3 (46.1) 46.6 (43.5) 49.3 (52.6) .61
(continued)
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Carbohydrate Metabolism
Based on fasting glucose level (available in 101 of 286 fasting
patients [34.0%]), prediabetes and diabetes were present in
4.0% and 3.0% of patients, respectively (Table 2 and Figure 2).
Prevalence figures for HbA1c-defined prediabetes and diabe-
tes were 15.4% and 2.9%, respectively. Hyperinsulinemia oc-
curred in 12.7% of patients and insulin resistance based on the
triglycerides to HDL-C ratio was present in 21.7%. Males had
significantly higher insulin resistance based on the triglycer-
ides to HDL-C ratio than females (P = .01), who had glucose-
defined diabetes significantly more often (3 females and 0
males; P = .04) (Table 2). Black patients had significantly higher
HbA1c-defined prediabetes than white patients (P < .001), who
had significantly higher triglycerides to HDL-C ratios than black
patients (P < .001) (Table 3).
Metabolic Syndrome
Among the patients, 13.2% had metabolic syndrome
(Table 2). While males fulfilled elevated blood pressure
criteria significantly more often than females (P = .02;
although more females received antihypertensive medica-
tion counting toward this criterion), abdominal obesity was
more than 3 times as common in females (45.6% in females
vs 14.7% in males; P < .001). This finding was independent
of the lower threshold for abdominal obesity in females
than males (>88 vs >102 cm, respectively), as females had
more abdominal obesity than males when using a threshold
greater than 102 cm for both groups (25.2% vs 14.7%, respec-
tively; P = .002) (Table 2). Consistent with continuous vari-
ables, significantly more white patients fulfilled hypertri-
glyceridemia (P < .001) and low HDL-C (P = .004) criteria
than black patients (Table 3).
Illness Duration and Cardiometabolic Risk
Abnormalities in each body composition parameter and tri-
glycerides to HDL-C ratio were associated with longer dura-
tion of psychiatric illness (mean [SD], 6.7 [6.7] years; median,
4.3 years) (Table 4). No other metabolic variables were signifi-
cantly associated with illness duration.
Antipsychotic Exposure and Cardiometabolic Risk
Duration of lifetime antipsychotic treatment was associated
with lower systolic blood pressure (P = .003) and greater ab-
normalities in measures of HDL-C (P = .02), non–HDL-C
(P = .01), triglycerides (P = .01), and triglycerides to HDL-C ratio
(P = .005) (Table 4). Although glucose level was inversely re-
lated to antipsychotic treatment duration (P = .02), results were
based on only 99 patients with data.
Compared with patients with any lifetime antipsychotic ex-
posure, antipsychotic-naive patients had lower non–HDL-C lev-
els (P = .04). However, more antipsychotic-naive patients were
obese (P = .01) and had hypertension (P = .03), and more patients
in this group fulfilled the abdominal obesity (P = .003) and el-
evated blood pressure (P = .03) criteria for metabolic syndrome,
which was also more frequent than in the antipsychotic-exposed
patients (P = .04) (eTable 1 in the Supplement).
Comparing baseline treatment groups, not using antipsy-
chotics at the time of blood draw was associated with signifi-
cantly lower levels of total cholesterol and low-density lipopro-
tein cholesterol (both P = .03). Moreover, higher levels of
triglycerides (P = .007), insulin (P = .02), and homeostasis model
assessment–estimated insulin resistance (P < .001) were asso-
ciated with olanzapine therapy, while a higher triglycerides to
HDL-C ratio was associated with quetiapine (P = .02) (eTable 2
in the Supplement).







(n = 106) P Value
Antipsychotic treatment, No. (%)
Risperidone 108 (27.4) 88 (30.6) 20 (18.9)
.17
None 54 (13.7) 33 (11.5) 21 (19.8)
Olanzapine 49 (12.4) 40 (13.9) 9 (8.5)
Antipsychotic polypharmacy 37 (9.4) 27 (9.4) 10 (9.4)
Aripiprazole 35 (8.9) 21 (7.3) 14 (13.2)
Paliperidone palmitate 34 (8.6) 23 (8.0) 11 (10.4)
Quetiapine fumarate 28 (7.1) 20 (6.9) 8 (7.6)
First-generation antipsychotic 26 (6.6) 18 (6.3) 8 (7.6)
Ziprasidone hydrochloride 12 (3.1) 9 (3.1) 3 (2.8)
Lurasidone hydrochloride 7 (1.9) 6 (2.1) 1 (0.9)
Clozapine 2 (0.5) 2 (0.7) 0
Asenapine 2 (0.5) 1 (0.4) 1 (0.9)
Nonantipsychotic comedication, No. (%)
Antidepressant 126 (32.0) 79 (27.4) 47 (44.3) .001
Anticholinergic 68 (17.3) 53 (18.4) 15 (14.2) .32
Antiepileptic, lithium carbonate,
or lithium citrate
48 (12.2) 36 (12.5) 12 (11.3) .75
Benzodiazepine 44 (11.2) 25 (8.7) 19 (18.1) .009
Nonbenzodiazepine hypnotic 20 (5.1) 13 (4.5) 7 (6.6) .40
Psychostimulant or
atomoxetine hydrochloride
6 (1.5) 5 (1.7) 1 (1.0) >.99
Abbreviations: IQR, interquartile
range; SCID, Structured Clinical
Interview for DSM-IV Axis I Disorders,
Patient Edition.
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(n = 106) P Value
NHANES
Age 20-29 y Age Mid-40s
Smoking, No. (%) (n = 394) 200 (50.8) 161 (55.9) 39 (36.8) <.001 36.7% for males,
24.9% for females42
Body composition
BMI, mean (SD) (n = 389) 26.6 (6.7) 26.3 (6.0) 27.3 (8.3) .17
Weight status, No. (%) (n = 389)
Underweight 8 (2.1) 3 (1.1) 5 (4.8)
.02
Normal 193 (49.6) 144 (50.7) 49 (46.7)
Overweight 102 (26.2) 81 (28.5) 21 (20.0)
Obese 86 (22.1) 56 (19.7) 30 (28.6) 25% (ages 20-24 y)43
Fat mass, mean (SD), kg (n = 373) 19.0 (14.3) 16.6 (13.4) 25.3 (16.3) <.001
Fat %, mean (SD) (n = 375) 22.7 (9.8) 19.0 (9.5) 32.5 (10.8) <.001
Waist circumference, mean (SD),
cm (n = 388)
91.1 (16.3) 91.1 (15.6) 91.2 (18.3) .95
Abdominal obesity, waist
circumference >102 cm for males
and females, No. (%) (n = 388)
68 (17.5) 42 (14.7) 26 (25.2) .002
Arterial blood pressure (n = 389)
Mean (SD), mm Hg
Systolic 117.1 (12.4) 120.1 (12.2) 108.6 (13.0) <.001
Diastolic 75.5 (9.9) 76.3 (9.6) 73.4 (10.7) .01
Prehypertension, blood pressure
120-139/80-89 mm Hg, No. (%)
155 (39.9) 134 (47.0) 21 (20.2) <.001 20.9%44
Hypertension, blood pressure
≥140/90 mm Hg, No. (%)
39 (10.0) 31 (10.9) 8 (7.7) .35 49.9%44
Fasting lipid metabolism (n = 286)a
Total cholesterol, mean (SD),
mg/dL
173.4 (35.5) 173.4 (37.2) 173.3 (30.5) .97
Hypercholesterolemia, total
cholesterol ≥200 mg/dL, No. (%)
61 (21.0) 46 (21.7) 15 (19.2) .65
LDL-C, mean (SD), mg/dL 100.7 (31.1) 101.4 (32.6) 99.9 (26.6) .56
Elevated LDL-C, ≥130 mg/dL,
No. (%)
49 (17.1) 38 (18.3) 11 (14.1) .40 27%35
Fasting and nonfasting HDL-C,
mean (SD), mg/dL (n = 304)
49.2 (12.8) 47.4 (12.0) 54.2 (14.6) <.001
Non–HDL-C, mean (SD), mg/dL 124.0 (35.8) 125.8 (37.8) 119.1 (29.9) .16
Elevated non–HDL-C, ≥130 mg/dL,
mean (SD)
116 (40.6) 89 (42.8) 27 (34.6) .21
Triglycerides, mean (SD), mg/dL 115.4 (77.5) 121.7 (84.9) 98.8 (52.9) .03
Hypertriglyceridemia, triglycerides
≥170 mg/dL, No. (%)
46 (16.1) 37 (17.8) 9 (11.5) .20 30%35
Dyslipidemia, No. (%)b 161 (56.5) 115 (55.6) 46 (59.0) .60 53%35
Fasting carbohydrate metabolisma
HbA1c, mean (SD), % (n = 280) 5.4 (0.7) 5.3 (0.4) 5.5 (1.1) .05
Glucose, mean (SD), mg/dL
(n = 100)c
86.4 (17.9) 85.2 (13.4) 88.6 (24.5) .37
Insulin, mean (SD), μIU/mL
(n = 235)c
11.6 (13.6) 11.8 (14.6) 11.1 (10.8) .71
Hyperinsulinemia, insulin
>20 μIU/mL, No. (%) (n = 235)
30 (12.7) 22 (12.9) 8 (12.3) .91
HOMA-IR, mean (SD) (n = 235)c 3.1 (3.8) 3.0 (3.4) 3.2 (4.4) .84
Triglycerides to HDL-C ratio
(n = 286)
Mean (SD) 2.6 (2.2) 2.9 (2.4) 2.1 (1.6) .01
Ratio ≥3.5, No. (%) 62 (21.7) 51 (24.5) 11 (14.1) .06
Prediabetes, No. (%)
Glucose based, 100-125 mg/dL
(n = 101)
4 (4.0) 3 (4.6) 1 (2.9) >.99
HbA1c based, 5.7%-6.4%
(n = 280)
43 (15.4) 27 (13.4) 16 (20.5) .14
Diabetes, No. (%)
Glucose based, >125 mg/dL
(n = 101)
3 (3.0) 0 3 (8.6) .04
HbA1c based, >6.4% (n = 280) 8 (2.9) 5 (2.5) 3 (3.9) .69
(continued)
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Discussion
Despite the young age of this study sample of 394 patients with
FES, an average of only 47 days of lifetime antipsychotic ex-
posure, and overweight and obesity figures comparable to
those for similarly aged US population members,43 there was
a clear pattern of increased smoking42 and several metabolic
risk indices41,44 compared with similarly aged persons in the
general US population. Moreover, dyslipidemia was as frequent
Figure 2. Prevalence of Smoking, Lipid Abnormalities, Hypertension, Diabetes, and Metabolic Syndrome



















































































































Dyslipidemia indicates an elevated
low-density lipoprotein cholesterol
(LDL-C) level (130 mg/dL; to
convert to millimoles per liter,
multiply by 0.0259), an elevated
non–high-density lipoprotein
cholesterol (HDL-C) level
(130 mg/dL; to convert to
millimoles per liter, multiply by
0.0259), an elevated triglycerides
level (150 mg/dL; to convert to
millimoles per liter, multiply by
0.0113), or a low HDL-C level
(<40 mg/dL in males and
<50 mg/dL in females; to convert to
millimoles per liter, multiply by
0.0259). HbA1c indicates
hemoglobin A1c.







(n = 106) P Value
NHANES
Age 20-29 y Age Mid-40s
Metabolic syndrome and individual criteria,
No. (%)
Metabolic syndrome, fasting glucose
≥100 mg/dL per ATP III (n = 257)
34 (13.2) 21 (11.2) 13 (18.6) .12 6.7%41, d 21.8%41,d
Low HDL-C, <40 mg/dL in males and
<50 mg/dL in females (n = 305)
91 (29.8) 61 (27.4) 30 (35.6) .12 37.1%41
Abdominal obesity, waist circumference
>102 cm in males and >88 cm in females
(n = 388)
89 (22.9) 42 (14.7) 47 (45.6) <.001 38.6%41
Elevated blood pressure, ≥130/80 mm Hg,
or antihypertensive treatment (n = 389)
92 (23.7) 76 (26.7) 16 (15.4) .02 34.0%41
Elevated triglycerides, ≥150 mg/dL
(n = 286)
62 (21.7) 50 (24.0) 12 (15.4) .11 30.0%41
Hyperglycemia, glucose ≥100 mg/dL
(n = 101)
7 (7.0) 3 (4.6) 4 (11.4) .69 12.6%41,d
Cardiometabolic treatment medication,
No. (%)
Antihypertensive 14 (3.6) 7 (2.4) 7 (6.6) .047
Antidiabetic 3 (0.8) 1 (0.4) 2 (1.9) .18
Lipid lowering 2 (0.5) 2 (0.7) 0 >.99
Abbreviations: ATP III, Adult Treatment Panel III; BMI, body mass index
(calculated as weight in kilograms divided by height in meters squared);
HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol;
HOMA-IR, homeostasis model assessment–estimated insulin resistance;
LDL-C, low-density lipoprotein cholesterol; NHANES, National Health and
Nutrition Examination Survey.
SI conversion factors: To convert fat mass to pounds, divide by 0.45; to convert
total cholesterol, LDL-C, HDL-C, and non–HDL-C to millimoles per liter, multiply
by 0.0259; to convert triglycerides to millimoles per liter, multiply by 0.0113; to
convert HbA1c from percentage of total hemoglobin to proportion of total
hemoglobin, multiply by 0.01; to convert glucose to millimoles per liter, multiply
by 0.0555; and to convert insulin to picomoles per liter, multiply by 6.945.
a Because HDL-C and HbA1c are not affected by time from last food ingestion,
their data include nonfasting patients.
b Defined as an elevated LDL-C level (130 mg/dL), non–HDL-C level
(130 mg/dL), or triglycerides level (150 mg/dL) or a low HDL-C level
(<40 mg/dL in males and <50 mg/dL in females).
c One patient with type 1 insulin-dependent diabetes was excluded from the
analysis of glucose, insulin, and HOMA-IR levels.
d The NHANES definition of metabolic syndrome uses a fasting glucose level of
110 mg/dL or higher as the glucose abnormality criterion instead of the
currently used metabolic syndrome definition with a fasting glucose threshold
of 100 mg/dL or higher.
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(n = 73) P Value
Smoking, No. (%) (n = 393) 117 (54.4) 70 (48.6) 9 (40.9) 4 (33.3) .29 172 (53.6) 28 (38.4) .02
Body composition
BMI, mean (SD) (n = 389) 26.2 (6.2) 27.5 (7.4) 26.2 (6.7) 23.0 (3.6) .08 26.7 (6.8) 26.1 (6.2) .52
Weight status, No. (%) (n = 389)




Normal 102 (47.9) 71 (50.4) 12 (54.6) 7 (58.3) 151 (47.9) 42 (59.2)
Overweight 61 (28.6) 31 (22.0) 6 (27.3) 4 (33.3) 85 (26.7) 17 (23.9)
Obese 45 (21.1) 38 (27.0) 3 (13.6) 0 74 (23.3) 12 (16.9)
Fat mass, mean (SD), kg (n = 373) 18.0 (12.9) 21.6 (17.6) 16.3 (13.6) 12.4 (5.8) .04a 19.5 (15.6) 16.6 (9.9) .14
Fat %, mean (SD) (n = 375) 21.8 (10.9) 24.6 (12.7) 20.6 (9.9) 18.9 (6.9) .07 22.8 (11.8) 22.1 (10.2) .68
Waist circumference,
mean (SD), cm (n = 387)
91.3 (14.3) 92.2 (19.0) 89.3 (17.8) 79.1 (8.3) .06 91.5 (16.8) 89.3 (13.7) .28
Arterial blood pressure (n = 388)
Mean (SD), mm Hg
Systolic 116.4 (12.7) 118.6 (14.2) 115.5 (14.9) 115.4 (14.2) .43 117.6 (13.2) 114.6 (14.1) .09
Diastolic 74.9 (9.5) 77.1 (10.6) 72.3 (9.6) 72.6 (8.1) .06 75.9 (9.5) 73.8 (11.5) .11
Prehypertension, blood pressure
120-139/80-89 mm Hg, No. (%)
90 (42.3) 50 (35.2) 10 (47.6) 5 (41.7) .51 128 (40.4) 27 (37.5) .65
Hypertension, blood pressure
≥140/90 mm Hg, No. (%)
19 (8.9) 20 (14.1) 0 0 .09 31 (9.8) 8 (11.1) .73
Fasting lipid metabolism (n = 286)b
Total cholesterol, mean (SD),
mg/dL
175.3 (35.7) 171.3 (35.8) 171.7 (36.6) 172.6 (25.6) .84 172.7 (34.8) 175.8 (37.7) .55
Hypercholesterolemia, total
cholesterol ≥200 mg/dL, No. (%)
36 (23.2) 19 (17.8) 5 (27.8) 1 (11.1) .54 46 (20.4) 15 (23.4) .59
LDL-C, mean (SD), mg/dL 102.8 (30.3) 99.3 (34.0) 97.2 (26.2) 93.0 (12.9) .65 100.2 (31.2) 102.7 (31.0) .58
Elevated LDL-C, ≥130 mg/dL,
No. (%)
30 (19.9) 15 (14.0) 4 (23.5) 0 .28 38 (17.1) 11 (17.5) .95
Fasting and nonfasting HDL-C,
mean (SD), mg/dL (n = 303)
46.3 (11.8) 53.0 (13.7) 50.2 (15.7) 53.1 (10.4) <.001c 49.7 (12.9) 47.5 (13.9) .24
Non–HDL-C, mean (SD), mg/dL 128.9 (36.2) 118.3 (36.1) 120.6 (33.1) 119.4 (23.3) .12 122.9 (35.9) 127.8 (35.8) .34
Elevated non–HDL-C,
≥130 mg/dL, mean (SD)
72 (47.4) 35 (32.7) 5 (29.4) 4 (44.4) .09 83 (37.2) 33 (52.4) .03




35 (22.9) 9 (8.4) 1 (5.9) 2 (22.2) .01 37 (16.5) 10 (15.9) .90
Dyslipidemia, No. (%)e 100 (66.2) 48 (44.9) 8 (47.1) 5 (55.6) .006 118 (53.2) 43 (68.3) .03
Fasting carbohydrate metabolismb
HbA1c, mean (SD), % (n = 279) 5.3 (0.8) 5.5 (0.4) 5.4 (0.5) 5.3 (0.2) .26 5.4 (0.7) 5.3 (0.3) .83
Glucose, mean (SD), mg/dL
(n = 100)f
87.4 (14.9) 85.4 (13.7) 83.6 (14.2) 68.7 (8.6) .17 86.0 (14.9) 83.9 (11.4) .60
Insulin, mean (SD), μIU/mL
(n = 234)f
10.8 (11.5) 12.8 (15.0) 18.1 (28.7) 8.4 (5.4) .23 11.9 (13.5) 12.1 (18.0) .94
Hyperinsulinemia, insulin
>20 μIU/mL, No. (%) (n = 234)
13 (10.9) 14 (15.4) 3 (18.8) 0 .46 25 (13.4) 5 (10.2) .64
HOMA-IR, mean (SD) (n = 234)f 3.7 (5.8) 3.1 (4.4) 4.8 (5.6) 0.9 (0.6) .70 3.4 (5.2) 3.5 (4.6) .93
Triglycerides to HDL-C ratio
(n = 285)
Mean (SD) 3.1 (2.3) 2.0 (1.8) 2.4 (1.6) 2.5 (1.6) <.001d 2.6 (2.1) 2.9 (1.9) .32
Ratio ≥3.5, No. (%) 46 (30.3) 11 (10.3) 2 (11.8) 3 (33.3) <.001 47 (21.1) 15 (23.8) .64
Prediabetes, No. (%)
Glucose based,
100-125 mg/dL (n = 101)
3 (7.1) 1 (2.2) 0 0 .60 3 (3.7) 1 (5.9) .54
HbA1c based,
5.7%-6.4% (n = 280)
12 (8.1) 31 (29.3) 1 (5.6) 0 <.001 36 (16.3) 8 (13.3) .58
Diabetes, No. (%)
Glucose based, >125 mg/dL
(n = 101)
2 (4.6) 1 (2.2) 0 0 .85 3 (3.6) 0 >.99
HbA1c based, >6.4% (n = 280) 3 (2.0) 5 (4.7) 1 (5.6) 0 .57 8 (3.6) 1 (1.7) .54
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as in adults 15 to 20 years older in the general US population.35
Further, body composition–related risk markers were signifi-
cantly associated with longer total psychiatric illness dura-
tion, whereas metabolic risk markers were significantly asso-
ciated with the overall very short mean lifetime antipsychotic
treatment duration. Finally, relevant for treatment choice and
recommendations for patients with FES, significantly higher
continuous metabolic risk factor values were associated with
olanzapine and less so with quetiapine.
Altogether, about half the patients with FES smoked to-
bacco or had dyslipidemia, 39.9% had prehypertension, 10.0%
were hypertensive, and a substantial minority (13.2%) had
metabolic syndrome. Furthermore, while 3.0% were already
diabetic, as many as 15.4% had HbA1c-defined prediabetes,
which has an 8-year risk for diabetes comparable to fasting glu-
cose–defined prediabetes.45 Smoking was dramatically more
frequent in our study’s patients than in young US adults in 2009
to 201142 (males: 55.9% vs 36.7%, respectively; females: 36.8%
vs 24.9%, respectively). Further, compared with 20- to 29-
year-olds in the general US population,43 metabolic syn-
drome was more prevalent in patients with FES (7.0% vs 13.2%,
respectively; +89%), although obesity was similarly common
as in US adults aged 20 to 24 years.43 Because that National
Health and Nutrition Examination Survey metabolic syn-
drome definition used a fasting glucose level of 110 mg/dL or
higher (to convert to millimoles per liter, multiply by 0.0555)41
instead of the now-used threshold of 100 mg/dL or higher40
as the glucose abnormality criterion, some of the observed dif-
ference may be influenced by this methodological differ-
ence. Additionally, the 56.5% dyslipidemia prevalence in pa-
tients with FES was at least as high as the 53% figure reported
for US adults averaging 20 years older.35 Prehypertension (sys-
tolic/diastolicbloodpressureof120-139/80-89mmHg)waspres-
ent in 39.9%, which was much more frequent than in 17 794
participants in the 1999 to 2006 National Health and Nutri-
tion Examination Survey (20.9%), whose average age was 20
years older,44 even if some of this difference may have been
due to the higher hypertension frequency in the older gen-
eral population sample. Although values in this first-episode
US sample were generally somewhat higher than those re-
ported in 3 European first-episode samples,46-48 the findings
converge in that the body weight and metabolic indices were















(n = 73) P Value
Metabolic syndrome and individual
criteria, No. (%)
Metabolic syndrome, fasting
glucose ≥100 mg/dL per ATP III
(n = 258)
24 (17.9) 8 (8.1) 2 (13.3) 0 .11 30 (14.5) 4 (8.0) .22
Low HDL-C, <40 mg/dL in males
and <50 mg/dL in females
(n = 304)
61 (37.4) 25 (21.9) 5 (27.8) 0 .008 69 (28.8) 22 (33.9) .43
Abdominal obesity, waist
circumference >102 cm in males
and >88 cm in females (n = 387)
49 (22.9) 37 (26.6) 3 (13.6) 0 .13 77 (24.3) 12 (16.7) .16
Elevated blood pressure,
≥130/80 mm Hg, or
antihypertensive treatment
(n = 388)
45 (21.1) 41 (28.9) 5 (23.8) 1 (8.3) .22 77 (24.3) 15 (20.8) .53
Elevated triglycerides,
≥150 mg/dL (n = 285)
47 (30.7) 11 (10.3) 2 (11.8) 3 (33.3) <.001 50 (22.3) 13 (20.6) .78
Hyperglycemia, glucose
≥100 mg/dL (n = 101)
5 (11.4) 2 (4.4) 0 0 .45 6 (7.1) 1 (5.9) >.99
Cardiometabolic treatment
medication, No. (%)
Antihypertensive 6 (2.8) 8 (5.6) 0 0 .35 13 (4.1) 1 (1.4) .48
Antidiabetic 1 (0.5) 2 (1.4) 0 0 .74 3 (0.9) 0 >.99
Lipid lowering 1 (0.5) 1 (0.7) 0 0 .96 2 (0.6) 0 >.99
Abbreviations: ATP III, Adult Treatment Panel III; BMI, body mass index
(calculated as weight in kilograms divided by height in meters squared);
HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol;
HOMA-IR, homeostasis model assessment–estimated insulin resistance;
LDL-C, low-density lipoprotein cholesterol.
SI conversion factors: To convert fat mass to pounds, divide by 0.45; to convert
total cholesterol, LDL-C, HDL-C, and non–HDL-C to millimoles per liter, multiply
by 0.0259; to convert triglycerides to millimoles per liter, multiply by 0.0113; to
convert HbA1c from percentage of total hemoglobin to proportion of total
hemoglobin, multiply by 0.01; to convert glucose to millimoles per liter, multiply
by 0.0555; and to convert insulin to picomoles per liter, multiply by 6.945.
a Greater for black patients than for white and Asian patients (P < .05, post hoc
pairwise t test).
b Because HDL-C and HbA1c are not affected by time from last food ingestion,
their data include nonfasting patients.
c Lower for white patients than for black patients (P < .05, post hoc pairwise
t test).
d Greater for white patients than for black patients (P < .05, post hoc pairwise
t test).
e Defined as an elevated LDL-C level (130 mg/dL), non–HDL-C level
(130 mg/dL), or triglycerides level (150 mg/dL) or a low HDL-C level
(<40 mg/dL in males and <50 mg/dL in females).
f One patient with type 1 insulin-dependent diabetes was excluded from the
analysis of glucose, insulin, and HOMA-IR levels.
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similar to those of the respective general population norms
prior to treatment and that cardiometabolic abnormalities
started to emerge early during antipsychotic exposure.
In our sample, body composition parameters, but not meta-
bolic parameters (except for the triglycerides to HDL-C ratio),
were significantly associated with longer psychiatric illness du-
ration, indicating potential adverse changes in diet, exercise,
and/or socioeconomic status related to psychiatric condi-
tions such as depression and emerging psychosis. However,
despite very short antipsychotic exposure, there was a signifi-
cant effect of antipsychotic treatment duration on disturbed
lipid metabolism and lipid-based proxy measures of early in-
sulin resistance,37 but not on body composition or carbohy-
drate metabolism indices. The latter may take longer to be sig-
nificantly dysregulated by antipsychotics, especially in young
patients, with the possible exception of olanzapine and
clozapine.19-21,23 Furthermore, longer antipsychotic treat-
ment was associated with lower systolic blood pressure,
consistent with the α-adrenergic blockade of many
antipsychotics.49
The relative contributions of schizophrenia, unhealthy life-
style, psychotropic treatment, and insufficient medical care
to elevated cardiovascular risk and mortality have been
debated.1-13,15-17,20-25 Comparing antipsychotic-naive patients
with nonnaive patients yielded only a few differences, includ-
ing higher frequencies of obesity, hypertension, and meta-
bolic syndrome (driven by more patients meeting abdominal
obesity and elevated blood pressure criteria) but less el-
evated non–HDL-C (a major risk factor for cardiovascular ill-
ness) in the antipsychotic-naive group than in patients with
lifetime antipsychotic exposure. These preliminary data are
partially driven by the hypotensive effect of antipsychotics and
the unexpectedly higher obesity rate in the antipsychotic-
naive group. Our results are limited by the relatively small
antipsychotic-naive sample and varying degrees of exposure
in the nonnaive group. Taken together, these data support the
view that cardiometabolic burden is partly due to psychiatric
or psychotic illness and unhealthy lifestyle but accelerates
after antipsychotics are initiated and taken for longer
periods.20-24
The finding that higher levels of triglycerides, insulin,
and insulin resistance were associated with olanzapine treat-
ment is consistent with a large body of evidence regarding
the cardiometabolic risk of olanzapine.20,21,24,50-53 That this
effect was observable this early is alarming and supports the
Schizophrenia Patient Outcomes Research Team’s recom-
mendation that clozapine and olanzapine should not be
given as first-line treatment in FES.54 The finding that a
higher triglycerides to HDL-C ratio, a marker of insulin resis-
tance, was associated with quetiapine treatment is concern-
ing. Together with other data suggesting a marked and early
adverse lipid signal with quetiapine despite similar weight
Table 4. Correlations Between Mean Continuous Cardiometabolic Health Parameters and Lifetime Durations






No. Spearman ρa P Value No. Spearman ρa P Value
Body composition
BMI 383 0.149 .003 388 0.047 .36
Fat mass 368 0.157 .002 373 0.044 .40
Fat % 370 0.156 .003 373 0.004 .93
Waist circumference 383 0.138 .007 388 −0.011 .98
Blood pressure
Systolic 384 0.008 .88 389 −0.152 .003
Diastolic 384 0.053 .30 389 −0.057 .27
Fasting blood lipidsb
Total cholesterol 283 0.097 .10 286 0.099 .10
LDL-C 282 0.076 .21 285 0.089 .14
HDL-C 301 −0.065 .26 304 −0.129 .02
Non–HDL-C 283 0.107 .07 286 0.151 .01
Triglycerides 283 0.115 .05 286 0.149 .01
Triglycerides to HDL-C ratio 281 0.125 .04 286 0.167 .005
Fasting carbohydrate metabolismb
HbA1c 277 −0.061 .31 278 −0.064 .29
Glucose 99 0.162 .11 100 −0.230 .02
Insulin 234 0.030 .64 235 −0.021 .76
HOMA-IR 89 0.158 .14 90 −0.159 .13
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided
by height in meters squared); HbA1c, hemoglobin A1c; HDL-C, high-density
lipoprotein cholesterol; HOMA-IR, homeostasis model assessment–estimated
insulin resistance; LDL-C, low-density lipoprotein cholesterol.
a Positive Spearman ρ indicates a direct relationship; negative Spearman ρ, an
inverse relationship.
b Because HDL-C and HbA1c are not affected by time from last food ingestion,
their data include nonfasting patients.
Cardiometabolic Risk and First-Episode Schizophrenia Spectrum Disorders Original Investigation Research
jamapsychiatry.com JAMA Psychiatry December 2014 Volume 71, Number 12 1359
Downloaded From: https://jamanetwork.com/ by a Non-Human Traffic (NHT) User  on 02/02/2021
Copyright 2014 American Medical Association. All rights reserved.
gain as risperidone,19-21,23,50 its first-line use in first-episode
psychosis may need to be reevaluated.
With few exceptions, compared with meta-analytically
pooled patients with FES enrolled in previous studies,55 this
real-world community sample had similar cardiometabolic risk
frequencies. Notable exceptions in our sample compared with
the other studies include higher rates of fasting glucose–
defined diabetes (2.9% vs 1.3%, respectively; +120%) and low
HDL-C (29.8% vs 21.9%, respectively; +36%). The frequency of
smoking in this FES sample (50.8%) was also similar to that of
prior FES samples55 but only modestly lower than in the most
recent population-based studies of patients of any age with
schizophrenia (59.1%).56 Of concern regarding future diabe-
tes risk, the HbA1c-based prediabetes frequency (15.4%) was
already 70% of that observed in patients with chronic schizo-
phrenia (21.6%) who were 16 years older.57
Importantly, the relatively high prevalences of hyperten-
sion, diabetes, and especially smoking and lipid abnor-
malities are in stark contrast to the lack of related medical
treatment in most patients. The underrecognition and
undertreatment of cardiometabolic risk factors, especially
lipid abnormalities, are consistent with previous reports
among patients with chronic schizophrenia12,14-16 and
antipsychotic-treated patients58-60 and are likely modifiable
reasons for premature mortality in schizophrenia.1-11 Fur-
thermore, smoking causes diseases that disproportionately
affect people with schizophrenia, including cardiovascular
disease, diabetes, cancers, and pulmonary diseases, and may
be a much stronger driver of cardiovascular morbidity and
mortality than obesity.61-65 Smoking cessation improves
health outcomes at any age, but quitting early provides the
most benefit.66 Together with the fact that no patients with
FES received nicotine replacement or medical interventions
for smoking, these findings suggest that early education,
engagement, and smoking cessation treatments are needed
for patients with FES.66
We observed several significant sex differences. Consis-
tent with the general population,67 females had greater fat
mass, higher fat percentage, more abdominal obesity, and more
glucose-based diabetes. Despite this, also as in the general
population, males had higher smoking rates, systolic and dia-
stolic blood pressure, prehypertension rates, triglycerides lev-
els, and triglycerides to HDL-C ratios and lower HDL-C levels.
Notably, we confirmed higher abdominal obesity rates in
females even when using the same waist circumference thresh-
old as in males. Abdominal obesity was similarly more preva-
lent in females in the chronic schizophrenia population of the
Clinical Antipsychotic Trials of Intervention Effectiveness
study.68 As in our sample, sex differences in metabolic syn-
drome were also not present among young people in the Na-
tional Health and Nutrition Examination Survey general popu-
lation survey but emerged among older people,67 particularly
among black and Hispanic patients.
Given that adiposity is a stronger predictor of cardiovas-
cular risk than BMI (which was similar between males and fe-
males in our sample), females with FES may be a particularly
high-risk cardiometabolic group. Nevertheless, arterial hyper-
tension and an increased triglycerides to HDL-C ratio, an early
indicator of insulin resistance,37 which were more prevalent
in males, are also cardiovascular risk factors. Thus, prospec-
tive studies are needed to assess how these different risk fac-
tors affect cardiovascular morbidity and mortality over time,
especially because antipsychotic treatment and potential
changes in healthy behaviors and socioeconomic status due
to chronic psychiatric illness further increase the risk.
No significant differences emerged between Hispanic and
non-Hispanic patients except that, consistent with general
population data,69,70 more non-Hispanic than Hispanic pa-
tients with FES smoked, while Hispanic patients with FES more
often had an elevated non–HDL-C level and dyslipidemia. How-
ever, several relevant racial differences emerged. Consistent
with the general population,71-74 despite greater fat mass,
black patients had significantly lower triglycerides levels and
triglycerides to HDL-C ratios than white patients. Contrary to
the triglycerides level and also similar to the general
population,75-77 black patients had HbA1c-defined prediabe-
tes significantly more often than white patients. A greater fre-
quency of HbA1c-defined prediabetes, which is a sign of im-
paired postprandial glycemic control, is alarming as retinopathy
starts at even lower HbA1c levels in black individuals than in
white individuals.78
Taken together, our findings highlight major opportuni-
ties for improvement in health care planning and delivery for
people with schizophrenia. Our data underscore that warn-
ings by the US Food and Drug Administration regarding dia-
betes risk of antipsychotics plus need for health monitoring
and subsequent national and international guidelines18 have
been insufficient to positively affect the health disparity for
patients with schizophrenia even at the beginning of their
treatment.12,14 Instead, there is a need for policy changes that
promote the implementation of integrated care, health homes,
and accountable care organizations wherein coordinated at-
tention to both physical and mental health care needs will lead
to improved health and reduced expenditure.6
Several limitations warrant attention. First, only 50 par-
ticipants were antipsychotic naive, making comparisons with
previously exposed patients preliminary. Second, the natu-
ralistic nature of antipsychotic treatment and multiple analy-
ses without adjustment for multiple testing limit our ability
to assign causality to differences in cardiometabolic risk be-
tween medication groups. In fact, differences in medica-
tions’ adverse effects may have been masked by clinicians’ se-
lective treatment of higher-risk (overweight or obese) patients
with lower-risk antipsychotics, eg, aripiprazole and ziprasi-
done hydrochloride. Moreover, glucose level was not part of
the initial research assessments and was therefore available
for only a subgroup. Furthermore, fat mass, fat percentage, and
insulin resistance were assessed with generalizable clinical
measures and not gold-standard techniques, and we did not
assess exercise or diet. Additionally, racial groups other than
white or black patients were small, as were some of the indi-
vidual antipsychotic treatment groups. Finally, data on the ex-
act history of type and sequence of antipsychotic treatment
prior to the baseline antipsychotic were not complete enough
to allow such analyses. Nevertheless, this is a large study of
patients with FES who had limited lifetime antipsychotic ex-
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posure and were recruited from 34 community treatment sites
in 21 states, which yielded results on cardiometabolic health
that are reflective of general clinical practice settings in the
United States. The limited number of eligible patients refus-
ing participation increases generalizability of the findings. That
78.4% of RAISE-ETP patients had at least 1 hospitalization is
likely due to the well-known problem that patients remained
untreated in the community and only received psychiatric at-
tention when symptoms became severe enough to warrant hos-
pitalization, and although unfortunate, this rate generalizes
to a broader US population. Furthermore, despite naturalistic
treatment, individual antipsychotic groups did not signifi-
cantly differ in duration of prior antipsychotic treatment, BMI,
fat mass, or waist circumference, reducing the potential bias
on laboratory measures and blood pressure.
Conclusions
Early in psychotic illness and after a mean of only 6.7 weeks
of antipsychotic exposure, lipid abnormalities and insulin
resistance markers were elevated and significantly related to
lifetime and individual antipsychotic exposure. These results
reinforce the importance of assessing all patients for cardio-
metabolic risk prior to and throughout treatment, choosing low-
risk antipsychotics, and managing cardiometabolic adverse ef-
fects that emerge in the care of patients with FES.12,20,21,79
Further research is needed to assess the trajectory of cardio-
metabolic risk, underlying mechanisms, and mediating vari-
ables, including preferred treatment choices for FES and/or
cardiometabolic risk factors.
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